ArticleNucleic acids research2020
SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology.
Article in Nucleic acids research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- A Machine Learning Approach for Predicting Synergism of Mixtures of Compounds in Treating Cancers.International journal of molecular sciences · 2026Article
- Unified heterogeneity-aware benchmark of drug synergy prediction: a cross-study analysis of traditional machine learning and graph deep learning models.Journal of cheminformatics · 2026Article
- CLC-Pred Synergy: Web Application for Predicting Pairwise Drug Combinations with Synergistic Activity Against NCI60 Cancer Cell Lines.International journal of molecular sciences · 2026Article
- Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery.Cancer research · 2026Article
- Few-shot drug synergy prediction via rapid cross-tier adaptation meta-optimization.Briefings in bioinformatics · 2025Article
- Optimizing kinase and PARP inhibitor combinations through machine learning and in silico approaches for targeted brain cancer therapy.Molecular diversity · 2025Article
- Identifying traditional Chinese medicine combinations for breast cancer treatment based on transcriptional regulation and chemical structure.Chinese medicine · 2025Article
- SynDRep: a synergistic partner prediction tool based on knowledge graph for drug repurposing.Bioinformatics advances · 2025Article
- Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.Cancer discovery · 2024Article
- Augmented drug combination dataset to improve the performance of machine learning models predicting synergistic anticancer effects.Scientific reports · 2024Article
- Optimizing drug combination and mechanism analysis based on risk pathway crosstalk in pan cancer.Scientific data · 2024Article
- A granularity-level information fusion strategy on hypergraph transformer for predicting synergistic effects of anticancer drugs.Briefings in bioinformatics · 2023Article
- Augmented drug combination dataset to improve the performance of machine learning models predicting synergistic anticancer effects.Research square · 2023Article
- Review of Predicting Synergistic Drug Combinations.Life (Basel, Switzerland) · 2023Review
- Precision oncology: a review to assess interpretability in several explainable methods.Briefings in bioinformatics · 2023Review
- Harmonizing across datasets to improve the transferability of drug combination prediction.Communications biology · 2023Article
- Machine learning methods, databases and tools for drug combination prediction.Briefings in bioinformatics · 2022Article
- ACDB: An Antibiotic Combination DataBase.Frontiers in pharmacology · 2022Article
- Using response surface models to analyze drug combinations.Drug discovery today · 2021Review
- DrugComb update: a more comprehensive drug sensitivity data repository and analysis portal.Nucleic acids research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Drug-combination data portals have recently been introduced to mine huge amounts of pharmacological data with the aim of improving current chemotherapy strategies. However, these portals have only been investigated for isolated datasets, and molecular profiles of cancer cell lines are lacking. Here we developed a cloud-based pharmacogenomics portal called SYNERGxDB (http://SYNERGxDB.ca/) that integrates multiple high-throughput drug-combination studies with molecular and pharmacological profiles of a large panel of cancer cell lines. This portal enables the identification of synergistic drug combinations through harmonization and unified computational analysis. We integrated nine of the largest drug combination datasets from both academic groups and pharmaceutical companies, resulting in 22 507 unique drug combinations (1977 unique compounds) screened against 151 cancer cell lines. This data compendium includes metabolomics, gene expression, copy number and mutation profiles of the cancer cell lines. In addition, SYNERGxDB provides analytical tools to discover effective therapeutic combinations and predictive biomarkers across cancer, including specific types. Combining molecular and pharmacological profiles, we systematically explored the large space of univariate predictors of drug synergism. SYNERGxDB constitutes a comprehensive resource that opens new avenues of research for exploring the mechanism of action for drug synergy with the potential of identifying new treatment strategies for cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.